ClinicalTrials.gg
Enrolling by invitationNCT07688720Updated Oct 23, 2026

Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause

An interventional study of transcutaneous auricular neurostimulation (tAN) in Perimenopause and PMDD, sponsored by Texas Christian University. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Texas Christian University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 23, 2026Now Enrolling by invitationPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Premenstrual Dysphoric Disorder with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Premenstrual Dysphoric Disorder · United States.

Planned enrollment
10th of 15
20 · median 45
Started
2026
with 1 other
No phase
7 of 19
1 open now
Registered
18th of 19
by date

Among the 19 studies in Premenstrual Dysphoric Disorder with a site in United States, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 18th registered.

Premenstrual Dysphoric Disorder

42 studies on the registry are indexed under Premenstrual Dysphoric Disorder; 10 are open to participants now.

Browse Premenstrual Dysphoric Disorder studies →

Open to participants now

4 of the 19 studies in Premenstrual Dysphoric Disorder with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Premenstrual Dysphoric Disorder studies recruiting now, 1 sets no upper age limit and 6 stop at 75 or younger; none take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Premenstrual Dysphoric Disorder with a site in United States, or all of them as a file.
02

Study summary

Transcutaneous Auricular Neurostimulation (tAN) will be administered to women with premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), and perimenopause. The investigators will examine whether tAN improves symptomology by collecting self-report data before the intervention, during the intervention, and following the intervention.

Read the detailed description

The PMS/PMDD study will last four menstrual cycles, for an average of four months in length. The first cycle will be baseline (pre-treatment), the next two cycles will be intervention (treatment), and one final cycle will be follow-up (post-treatment).

The perimenopause study will last three months. The first month will be baseline (pre-treatment), the next month will be intervention (treatment), and the final month will be follow-up (post-treatment).

03

Conditions studied

  • Perimenopause
  • PMDD

Keywords

  • Premenstrual Symptoms
  • Menopause
  • Women's health
  • Perimenopause
  • Premenstrual Dysphoric Disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

PMS/PMDD Study:

Inclusion Criteria:

  • Assigned female at birth
  • Age 18 to 45
  • Naturally cycling
  • Regularly occurring menstrual cycle
  • Must identify as having PMS or PMDD
  • Reliable ability to complete online study surveys

Exclusion Criteria:

  • Using hormonal
  • Pregnant or lactating/breastfeeding
  • History of seizures
  • Implanted devices
  • Current or previous diagnosis of any heart conditions
  • Abnormal ear anatomy
  • Non-removable piercings on the ear
  • Recent ear infection
  • Taking SSRIs
  • Taking
  • Taking hormone therapy
  • If the participant anticipates starting or stopping prescription medications during the study period
  • Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.)
  • Participant has a history traumatic brain injury within the past 12 months
  • Must not have any other mental illness or mood disorder

Perimenopause Study:

Inclusion Criteria:

  • Assigned female at birth.
  • Age 40 to 55
  • Must have newly variable menstrual cycles or report identifying as perimenopausal
  • Reliable ability to complete online study surveys

Exclusion Criteria:

  • Using hormonal birth control
  • Pregnant or lactating/breastfeeding
  • History of seizures
  • Implanted devices
  • Current or previous diagnosis of any heart conditions
  • Abnormal ear anatomy
  • Non-removable piercings on the ear
  • Recent ear infection
  • Taking SSRIs
  • Taking steroids
  • Taking hormone therapy
  • If the participant anticipates starting or stopping prescription medications during the study period.
  • Participant has a history of neurologic diseases (i.e. stroke, brain tumor, cerebrovascular, etc.)
  • Participant has a history traumatic brain injury within the past 12 months
  • have a hysterectomy

In both studies we will confirm that participants are symptomatic shortly following enrollment.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    tAN treatment

    For perimenopausal women: tAN administration 2 hours daily. For PMS/PMDD women: tAN administration 2 hours daily during the luteal phase.

    Device: transcutaneous auricular neurostimulation (tAN)

Interventions

  • Devicetranscutaneous auricular neurostimulation (tAN)

    Device: Sparrow Link. The Sparrow Link will be using the components of the Sparrow Ascent device: (FDA-cleared K230796) a wearable, battery-operated, neurostimulation system designed to transcutaneously stimulate nerves on and/or around the auricle. This device will stimulate the auriculotemporal nerve (ATN) and the auricular branch of the vagus nerve (ABVN)

    Also known as: Sparrow Link

06

What researchers measure

Primary outcomes

  1. Daily Record of Severity of Problems (DRSP)

    The DRSP assesses psychological and physical premenstrual symptoms. This is the primary outcome in the PMS/PMDD study.

    Time frame: Assessed daily from study initiation until the end of the study, an average of four months (4 cycles). Menstrual cycle length varies but is generally 21-35 days.

  2. Green Climacteric Scale

    The Green Climacteric Scale assesses the degree to which respondents are bothered by a range of different menopausal symptoms. This is the primary outcome in the Perimenopause Study.

    Time frame: Participants will complete this measure monthly from study initiation until the end of the study, about three months.

Secondary outcomes

  1. Daily Mood

    Each day, participants will be asked to respond to the question "How is your mood today?". Response options range from 1 = extremely bad/negative to 7 = extremely good/positive. This is a secondary outcome in both studies.

    Time frame: Participants will fill this out daily from study initiation until the end of the study, about 3 months in the perimenopause study and 4 months in the PMS/PMDD study (4 cycles). Menstrual cycle length varies but is generally 21-35 days.

  2. Daily Hot Flash Frequency

    Hot flash frequency will be assessed. This is a secondary outcome in the Perimenopause Study.

    Time frame: Participants will respond to questions about hot flash frequency daily from study initiation until the end of the study, about three months.

  3. Daily Hot Flash Severity

    Hot flash severity will be assessed. This is a secondary outcome in the Perimenopause Study.

    Time frame: Participants will respond to questions about hot flash severity daily from study initiation until the end of the study, about three months.

  4. Daily Sleep Quality

    Each day, participants will be asked to respond to the question, "How well did you sleep last night?". Response options range from 1 = Very poor to 5 = Excellent. This is a secondary outcome in the Perimenopause study.

    Time frame: Participants will respond to this question daily from study initiation until the end of the study, about three months.

  5. Premenstrual Symptoms Screening Tool (PSST)

    The PSST evaluates severity of premenstrual symptoms. This is a secondary outcome in the PMS/PMDD study.

    Time frame: Participants will complete this measure each cycle from study initiation until the end of the study, about four months (4 cycles). Menstrual cycle length varies but is generally 21-35 days.

  6. Depression (PHQ-8)

    Each cycle participants will complete the Patient Health Questionnaire-8 (PHQ-8) that assesses depression. In both studies this is a secondary outcome.

    Time frame: Participants will complete this measure each month/cycle from study initiation until the end of the study, about 3 months in the perimenopause study and 4 months in the PMS/PMDD study (4 cycles). Menstrual cycle length varies but is generally 21-35 days.

  7. Anxiety (GAD-7)

    Each cycle/month participants will complete the Generalized Anxiety Disorder-7 (GAD-7) scale that assesses anxiety symptoms. This is a secondary outcome in both studies.

    Time frame: Participants will complete this measure each cycle/month from study initiation until the end of the study, about 3 months in the perimenopause study and 4 months in the PMS/PMDD study (4 cycles). Menstrual cycle length varies but is generally 21-35 days.

  8. Insomnia Severity Index (ISI)

    Assesses sleep quality and sleep issues. This is a secondary outcome in both studies.

    Time frame: Participants will complete the ISI each cycle or monthly from study initiation until the end of the study, about 3 months in the perimenopause study and 4 months in the PMS/PMDD study (4 cycles). Menstrual cycle length varies but is generally 21-35 days.

  9. Positive and Negative Affect Schedule (PANAS)

    The PANAS is a self-report measure of a range of positive and negative emotions participants may be experiencing. This is a secondary outcome in both studies.

    Time frame: Participants will complete the PANAS each month/cycle from study initiation until the end of the study, about 3 months in the perimenopause study and 4 months in the PMS/PMDD study (4 cycles). Menstrual cycle length varies but is generally 21-35 days.

  10. Menopause Quality of Life Questionnaire

    The Menopause Quality of Life Questionnaire measures how frequently participants have been bothered by a range of different menopausal symptoms. This is a secondary outcome in the Perimenopause Study.

    Time frame: Participants will respond to this questionnaire monthly from study initiation until the end of the study, about three months.

  11. Device Usability Questionnaire

    Questionnaire designed to assess participants' overall satisfaction with the device and to evaluate how easily they were able to operate it using the provided instructions and support materials. This is a secondary outcome in both studies.

    Time frame: This will be administered at the end of the treatment period. Perimenopause study: this will be administered after month 2 (out of 3). PMS/PMDD study: this will be administered after cycle 3 (out of 4). Cycle length varies but is generally 21-35 days.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Primary and secondary outcomes will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: The investigators will share data at the time of publication. There will be no end date, data will be made available indefinitely.

Access criteria: The investigators will post the deidentified data on open science framework, meaning that it will be publicly available for any researchers who wish to download it.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Mar 2028, 17 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Sep 29, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Mar 2028, on Oct 23, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Jun 2028, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jul 7, 2026
StartActual
Oct 22, 2026was Jun 2026
Primary completionEst.
Mar 2028was Mar 2027
CompletionEst.
Jun 2028was Mar 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 23, 2026
Start date
Jun 2026→Oct 2026
Sep 29, 2026
Primary completion
Mar 2027→Mar 2028
Oct 23, 2026
Study completion
Mar 2027→Jun 2028
Oct 23, 2026
Contact
No study contact listed any more: removed s•••@tcu.edu · •••6424; removed s•••@tcu.edu · •••4989
Oct 23, 2026
Show all 2 updates
  1. Oct 23, 2026
    Recruiting→Enrolling by invitation
    Primary completion Mar 2027→Mar 2028
    Study completion Mar 2027→Jun 2028
    Contact No study contact listed any more: removed s•••@tcu.edu · •••6424; removed s•••@tcu.edu · •••4989
    + 2 other changes: verification date and site details
  2. Sep 29, 2026
    Start date Jun 2026→Oct 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07688720
Lead sponsor
Texas Christian University
Collaborators
Spark Biomedical, Inc.
Responsible party
Sarah Hill (Professor, Texas Christian University) — Principal investigator
First posted
Jul 7, 2026
Start date
Oct 22, 2026
Primary completion
Mar 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Sarah E Hill, PhD
principal investigator · Texas Christian University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion